Strainprint™ Technologies Ltd., Gynica Lumir Lab to release custom questionnaire to select eligible participants for world-leading medical cannabis research
TORONTO, Aug. 7, 2019 /CNW/ – Strainprint™ Technologies Ltd. is pleased to launch the next stage of the much-anticipated clinical trial with Israeli based research group Gynica to develop a product formulation to treat endometriosis and its symptoms. This phase will include asking endometriosis sufferers in Canada and Israel to complete an anonymous, comprehensive custom questionnaire about how they use cannabis to treat their symptoms.
Strainprint, the leader in cannabis data and analytics partnered with Israeli researchers at Gynica, a leader in cannabis-based solutions for women’s health, in late 2018 to conduct the world’s first international clinical study on the use of cannabis to treat endometriosis. The study will leverage Strainprint’s database of patient reported outcomes among those who use cannabis to